Life Sciences Ontario
Life Sciences Ontario (LSO) strives to be the unified Voice of Life Sciences in Ontario by representing the interests of the diverse life sciences community in the province through advocacy, education, facilitation of economic development and promotion of the industry locally, nationally and internationally. Together we are a strong, innovative sector with significant socioeconomic contributions to the province of Ontario. We hope you will consider joining LSO and help us to achieve our vision for Ontario'€™s life sciences sector - "Diversity of Members, Unity of Voice".

PlantForm Corporation to Receive Additional Federal Funding for Work on Anti-Nerve-Agent Enzyme  

Tuesday, November 4, 2015

The project scope and value of a Government of Canada contract awarded to PlantForm Corporation has been increased after the company achieved a key milestone ahead of schedule. The three-year contract has been amended to provide an additional $109,400 for work to scale-up a process that yields sialylated plant-made butyrylcholinesterase (BuChE) in order to produce sufficient material for a pharmacokinetic study.

[Read more here]

OICR, UHN, Novera Therapeutics Announce Collaboration with Johnson & Johnson Innovation on Drug Discovery and Development for Haematological Cancers

Thursday, October 15, 2015

TORONTO, Oct. 14, 2015 /CNW/ - The Ontario Institute for Cancer Research ("OICR") together with Novera Therapeutics Inc., ("Novera") have announced a collaboration with Janssen Biotech, LLC ("Janssen"), a Pharmaceutical company of Johnson & Johnson, to accelerate the development of promising small molecule drug candidates for haematological cancers. Novera, a new Ontario biotechnology company, will discover and develop novel therapeutic compounds identified through OICR's drug discovery program in partnership with University Health Network's ("UHN") enabling technology and disease area biology, and coordinate the collaboration with Janssen under a collaboration, license option, and exclusive license agreement (the "agreement").

[Read more here]

Encycle Therapeutics raises $2.85 million to advance macrocycle platform and pipeline

Wednesday, September 30, 2015

Encycle Therapeutics, Inc., a University of Toronto spin-off company created in partnership with MaRS Innovation, announced today that it has completed a $2.85 million (CAD) financing led by Takeda Pharmaceutical Company Ltd. through its venture capital arm, Takeda Ventures, Inc., with Accel-Rx Health Sciences Accelerator, BDC Capital and MaRS Investment Accelerator Fund.

[Read more here]

Biotechnology Focus and Stratford Managers Corporation Launch Life Sciences Employee Opinion Survey

Wednesday, September 30, 2015

Biotechnology Focus, Canadas leading life science journal, has announced a collaboration with Stratford Managers Corporation for the first-ever life science HR survey. The findings will be published in a report to be featured in Biotechnology Focus Magazine, as well as through social media channels. One of the goals of this project is to celebrate Canadian life science success stories and the people whose talent, drive and intellectual property are key assets for the future of the industry.

[Read more here]

Toronto-based biotech startup wins recognition at BioPharm America 2015 during Johnson & Johnson Innovation Startup Day competition

Wednesday, September 23, 2015

EBD Group today announced the winners of the first annual Johnson & Johnson Innovation Biotech Startup Day competition at the eighth annual BioPharm America™ 2015 life science partnering event in Boston.  The winner of the Johnson & Johnson Innovation Startup Day competition grand prize went to Proteorex Therapeutics Inc. for their innovative technology and services to support drug discovery.

[ Read more here]